nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisapride—CYP2A6—Nevirapine—acquired immunodeficiency syndrome	0.0346	0.0365	CbGbCtD
Cisapride—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0239	0.0253	CbGbCtD
Cisapride—CYP2A6—Zidovudine—acquired immunodeficiency syndrome	0.0227	0.024	CbGbCtD
Cisapride—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0225	0.0238	CbGbCtD
Cisapride—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0225	0.0238	CbGbCtD
Cisapride—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0214	0.0226	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0214	0.0226	CbGbCtD
Cisapride—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0204	0.0215	CbGbCtD
Cisapride—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0185	0.0195	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0185	0.0195	CbGbCtD
Cisapride—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0179	0.0189	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0179	0.0189	CbGbCtD
Cisapride—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0177	0.0187	CbGbCtD
Cisapride—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0171	0.018	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0162	0.0171	CbGbCtD
Cisapride—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0162	0.0171	CbGbCtD
Cisapride—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0162	0.0171	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0162	0.0171	CbGbCtD
Cisapride—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.016	0.0169	CbGbCtD
Cisapride—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.016	0.0169	CbGbCtD
Cisapride—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0154	0.0163	CbGbCtD
Cisapride—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0154	0.0163	CbGbCtD
Cisapride—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0154	0.0163	CbGbCtD
Cisapride—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0152	0.0161	CbGbCtD
Cisapride—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0143	0.0151	CbGbCtD
Cisapride—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.014	0.0148	CbGbCtD
Cisapride—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0138	0.0146	CbGbCtD
Cisapride—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0134	0.0142	CbGbCtD
Cisapride—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0132	0.0139	CbGbCtD
Cisapride—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0132	0.0139	CbGbCtD
Cisapride—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0129	0.0137	CbGbCtD
Cisapride—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0129	0.0137	CbGbCtD
Cisapride—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0127	0.0134	CbGbCtD
Cisapride—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0122	0.0128	CbGbCtD
Cisapride—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0122	0.0128	CbGbCtD
Cisapride—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0119	0.0126	CbGbCtD
Cisapride—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0119	0.0126	CbGbCtD
Cisapride—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0126	CbGbCtD
Cisapride—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0117	0.0123	CbGbCtD
Cisapride—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0117	0.0123	CbGbCtD
Cisapride—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0116	0.0122	CbGbCtD
Cisapride—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0112	0.0118	CbGbCtD
Cisapride—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0112	0.0118	CbGbCtD
Cisapride—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0109	0.0115	CbGbCtD
Cisapride—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0109	0.0115	CbGbCtD
Cisapride—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0108	0.0114	CbGbCtD
Cisapride—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0114	CbGbCtD
Cisapride—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0114	CbGbCtD
Cisapride—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.01	0.0106	CbGbCtD
Cisapride—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00984	0.0104	CbGbCtD
Cisapride—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00984	0.0104	CbGbCtD
Cisapride—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00981	0.0103	CbGbCtD
Cisapride—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00981	0.0103	CbGbCtD
Cisapride—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0094	0.00992	CbGbCtD
Cisapride—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00929	0.0098	CbGbCtD
Cisapride—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00905	0.00955	CbGbCtD
Cisapride—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00902	0.00951	CbGbCtD
Cisapride—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00849	0.00896	CbGbCtD
Cisapride—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00824	0.0087	CbGbCtD
Cisapride—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00815	0.0086	CbGbCtD
Cisapride—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00815	0.0086	CbGbCtD
Cisapride—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00782	0.00825	CbGbCtD
Cisapride—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00746	0.00787	CbGbCtD
Cisapride—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00746	0.00787	CbGbCtD
Cisapride—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00736	0.00776	CbGbCtD
Cisapride—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00692	0.0073	CbGbCtD
Cisapride—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00692	0.0073	CbGbCtD
Cisapride—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00626	0.0066	CbGbCtD
Cisapride—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00626	0.0066	CbGbCtD
Cisapride—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0054	0.0057	CbGbCtD
Cisapride—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00524	0.00553	CbGbCtD
Cisapride—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00474	0.005	CbGbCtD
Cisapride—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00474	0.005	CbGbCtD
Cisapride—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00455	0.0048	CbGbCtD
Cisapride—HTR3A—nerve—acquired immunodeficiency syndrome	0.00268	0.0566	CbGeAlD
Cisapride—HTR4—brain—acquired immunodeficiency syndrome	0.00171	0.036	CbGeAlD
Cisapride—DRD2—nerve—acquired immunodeficiency syndrome	0.00164	0.0346	CbGeAlD
Cisapride—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00128	0.027	CbGeAlD
Cisapride—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00112	0.0236	CbGeAlD
Cisapride—HTR2A—nerve—acquired immunodeficiency syndrome	0.00108	0.0228	CbGeAlD
Cisapride—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00105	0.0221	CbGeAlD
Cisapride—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.00101	0.0213	CbGeAlD
Cisapride—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.001	0.0212	CbGeAlD
Cisapride—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000994	0.021	CbGeAlD
Cisapride—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000922	0.0194	CbGeAlD
Cisapride—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000819	0.0173	CbGeAlD
Cisapride—HTR3A—digestive system—acquired immunodeficiency syndrome	0.00078	0.0164	CbGeAlD
Cisapride—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000758	0.016	CbGeAlD
Cisapride—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000746	0.0157	CbGeAlD
Cisapride—HTR3A—blood—acquired immunodeficiency syndrome	0.000743	0.0157	CbGeAlD
Cisapride—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000737	0.0155	CbGeAlD
Cisapride—DRD2—retina—acquired immunodeficiency syndrome	0.00068	0.0143	CbGeAlD
Cisapride—CYP2A6—vagina—acquired immunodeficiency syndrome	0.000677	0.0143	CbGeAlD
Cisapride—HTR3A—lung—acquired immunodeficiency syndrome	0.000652	0.0137	CbGeAlD
Cisapride—CYP2A6—lung—acquired immunodeficiency syndrome	0.00064	0.0135	CbGeAlD
Cisapride—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000603	0.0127	CbGeAlD
Cisapride—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000589	0.0124	CbGeAlD
Cisapride—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000581	0.0122	CbGeAlD
Cisapride—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000576	0.0121	CbGeAlD
Cisapride—HTR2B—blood—acquired immunodeficiency syndrome	0.000562	0.0118	CbGeAlD
Cisapride—HTR2B—vagina—acquired immunodeficiency syndrome	0.000521	0.011	CbGeAlD
Cisapride—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000493	0.0104	CbGeAlD
Cisapride—HTR2B—lung—acquired immunodeficiency syndrome	0.000492	0.0104	CbGeAlD
Cisapride—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000485	0.0102	CbGeAlD
Cisapride—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000482	0.0102	CbGeAlD
Cisapride—CYP2C19—blood—acquired immunodeficiency syndrome	0.00047	0.0099	CbGeAlD
Cisapride—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000467	0.00985	CbGeAlD
Cisapride—HTR3A—brain—acquired immunodeficiency syndrome	0.000461	0.00972	CbGeAlD
Cisapride—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000456	0.00961	CbGeAlD
Cisapride—CYP2A6—brain—acquired immunodeficiency syndrome	0.000453	0.00955	CbGeAlD
Cisapride—HTR2A—retina—acquired immunodeficiency syndrome	0.000448	0.00945	CbGeAlD
Cisapride—KCNH2—blood—acquired immunodeficiency syndrome	0.000448	0.00945	CbGeAlD
Cisapride—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000439	0.00925	CbGeAlD
Cisapride—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000435	0.00918	CbGeAlD
Cisapride—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000433	0.00914	CbGeAlD
Cisapride—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000432	0.0091	CbGeAlD
Cisapride—KCNH2—vagina—acquired immunodeficiency syndrome	0.000415	0.00876	CbGeAlD
Cisapride—CYP2C8—blood—acquired immunodeficiency syndrome	0.00041	0.00864	CbGeAlD
Cisapride—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000403	0.00849	CbGeAlD
Cisapride—DRD2—lung—acquired immunodeficiency syndrome	0.000399	0.0084	CbGeAlD
Cisapride—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000391	0.00824	CbGeAlD
Cisapride—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000388	0.00819	CbGeAlD
Cisapride—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000386	0.00814	CbGeAlD
Cisapride—CYP1A2—blood—acquired immunodeficiency syndrome	0.000384	0.00809	CbGeAlD
Cisapride—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000382	0.00806	CbGeAlD
Cisapride—CYP2C8—vagina—acquired immunodeficiency syndrome	0.00038	0.00801	CbGeAlD
Cisapride—HTR2C—brain—acquired immunodeficiency syndrome	0.000371	0.00782	CbGeAlD
Cisapride—CYP3A5—blood—acquired immunodeficiency syndrome	0.00037	0.0078	CbGeAlD
Cisapride—DRD2—nervous system—acquired immunodeficiency syndrome	0.000369	0.00778	CbGeAlD
Cisapride—CYP2B6—blood—acquired immunodeficiency syndrome	0.000368	0.00775	CbGeAlD
Cisapride—CYP2C9—blood—acquired immunodeficiency syndrome	0.000364	0.00768	CbGeAlD
Cisapride—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000364	0.00767	CbGeAlD
Cisapride—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000355	0.00749	CbGeAlD
Cisapride—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.00035	0.00738	CbGeAlD
Cisapride—HTR2B—brain—acquired immunodeficiency syndrome	0.000348	0.00735	CbGeAlD
Cisapride—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000343	0.00723	CbGeAlD
Cisapride—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000341	0.00719	CbGeAlD
Cisapride—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000337	0.0071	CbGeAlD
Cisapride—CYP1A2—lung—acquired immunodeficiency syndrome	0.000336	0.00709	CbGeAlD
Cisapride—CYP3A5—lung—acquired immunodeficiency syndrome	0.000324	0.00684	CbGeAlD
Cisapride—CYP2B6—lung—acquired immunodeficiency syndrome	0.000322	0.0068	CbGeAlD
Cisapride—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000315	0.00664	CbGeAlD
Cisapride—HTR2A—blood—acquired immunodeficiency syndrome	0.0003	0.00632	CbGeAlD
Cisapride—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000298	0.00629	CbGeAlD
Cisapride—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000291	0.00614	CbGeAlD
Cisapride—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000289	0.00609	CbGeAlD
Cisapride—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000287	0.00606	CbGeAlD
Cisapride—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000287	0.00605	CbGeAlD
Cisapride—DRD2—brain—acquired immunodeficiency syndrome	0.000282	0.00595	CbGeAlD
Cisapride—HTR2A—vagina—acquired immunodeficiency syndrome	0.000278	0.00586	CbGeAlD
Cisapride—KCNH2—brain—acquired immunodeficiency syndrome	0.000278	0.00586	CbGeAlD
Cisapride—CYP3A4—blood—acquired immunodeficiency syndrome	0.000278	0.00585	CbGeAlD
Cisapride—CYP2D6—blood—acquired immunodeficiency syndrome	0.000273	0.00576	CbGeAlD
Cisapride—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000269	0.00566	CbGeAlD
Cisapride—HTR2A—lung—acquired immunodeficiency syndrome	0.000263	0.00554	CbGeAlD
Cisapride—CYP2C8—brain—acquired immunodeficiency syndrome	0.000254	0.00536	CbGeAlD
Cisapride—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000243	0.00513	CbGeAlD
Cisapride—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000234	0.00494	CbGeAlD
Cisapride—CYP2B6—brain—acquired immunodeficiency syndrome	0.000228	0.00481	CbGeAlD
Cisapride—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000225	0.00475	CbGeAlD
Cisapride—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000222	0.00468	CbGeAlD
Cisapride—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000217	0.00457	CbGeAlD
Cisapride—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000214	0.0045	CbGeAlD
Cisapride—HTR2A—brain—acquired immunodeficiency syndrome	0.000186	0.00392	CbGeAlD
Cisapride—CYP2D6—brain—acquired immunodeficiency syndrome	0.00017	0.00357	CbGeAlD
Cisapride—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	1.69e-05	0.00343	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	1.69e-05	0.00343	CbGpPWpGaD
Cisapride—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	1.67e-05	0.00338	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	1.65e-05	0.00335	CbGpPWpGaD
Cisapride—HTR2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	1.64e-05	0.00333	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	1.62e-05	0.00329	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.62e-05	0.00329	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.00321	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.57e-05	0.00319	CbGpPWpGaD
Cisapride—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	1.57e-05	0.00318	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	1.56e-05	0.00315	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.55e-05	0.00315	CbGpPWpGaD
Cisapride—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	1.54e-05	0.00313	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.53e-05	0.0031	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.52e-05	0.00309	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.52e-05	0.00309	CbGpPWpGaD
Cisapride—HTR2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.00306	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.44e-05	0.00292	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.44e-05	0.00292	CbGpPWpGaD
Cisapride—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.44e-05	0.00291	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.43e-05	0.0029	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.43e-05	0.0029	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.0029	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.42e-05	0.00288	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.41e-05	0.00286	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.41e-05	0.00286	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.41e-05	0.00285	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.4e-05	0.00285	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	1.37e-05	0.00278	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.37e-05	0.00278	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.36e-05	0.00277	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.00273	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.00273	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.32e-05	0.00268	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.32e-05	0.00268	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.31e-05	0.00265	CbGpPWpGaD
Cisapride—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.00262	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.00261	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	1.29e-05	0.00261	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.27e-05	0.00258	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.26e-05	0.00255	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.23e-05	0.0025	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.23e-05	0.00249	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	1.22e-05	0.00247	CbGpPWpGaD
Cisapride—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.00247	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.2e-05	0.00244	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.18e-05	0.0024	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.18e-05	0.0024	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	1.18e-05	0.00239	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.16e-05	0.00235	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.16e-05	0.00235	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.00235	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.00235	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.15e-05	0.00233	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.13e-05	0.0023	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.11e-05	0.00225	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.11e-05	0.00225	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.1e-05	0.00224	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.09e-05	0.00222	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.09e-05	0.00221	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—TAT—acquired immunodeficiency syndrome	1.08e-05	0.00219	CbGpPWpGaD
Cisapride—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.00218	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.07e-05	0.00217	CbGpPWpGaD
Cisapride—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.06e-05	0.00215	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.00212	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.02e-05	0.00208	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.02e-05	0.00208	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.02e-05	0.00208	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.00207	CbGpPWpGaD
Cisapride—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.01e-05	0.00206	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.01e-05	0.00204	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.01e-05	0.00204	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.01e-05	0.00204	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	1e-05	0.00203	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1e-05	0.00203	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	9.91e-06	0.00201	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.85e-06	0.002	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.84e-06	0.002	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.8e-06	0.00199	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.75e-06	0.00198	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.59e-06	0.00195	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.21e-06	0.00187	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—AGPS—acquired immunodeficiency syndrome	9.19e-06	0.00186	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.06e-06	0.00184	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	9.04e-06	0.00183	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.9e-06	0.0018	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	8.88e-06	0.0018	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	8.88e-06	0.0018	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.82e-06	0.00179	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	8.72e-06	0.00177	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.68e-06	0.00176	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.64e-06	0.00175	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	8.52e-06	0.00173	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.45e-06	0.00171	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.32e-06	0.00169	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.3e-06	0.00168	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.3e-06	0.00168	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.2e-06	0.00166	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.12e-06	0.00165	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.12e-06	0.00165	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.95e-06	0.00161	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.85e-06	0.00159	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.79e-06	0.00158	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.66e-06	0.00155	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.61e-06	0.00154	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.5e-06	0.00152	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.44e-06	0.00151	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	7.42e-06	0.0015	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	7.38e-06	0.0015	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.38e-06	0.0015	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.38e-06	0.0015	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	7.25e-06	0.00147	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.01e-06	0.00142	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7e-06	0.00142	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.97e-06	0.00141	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.9e-06	0.0014	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.69e-06	0.00136	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.69e-06	0.00136	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	6.66e-06	0.00135	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	6.59e-06	0.00134	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.55e-06	0.00133	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.55e-06	0.00133	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.33e-06	0.00128	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	6.28e-06	0.00127	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.18e-06	0.00125	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.18e-06	0.00125	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.15e-06	0.00125	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.09e-06	0.00123	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.08e-06	0.00123	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	6.06e-06	0.00123	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.05e-06	0.00123	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.05e-06	0.00123	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	6.01e-06	0.00122	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.95e-06	0.00121	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.95e-06	0.00121	CbGpPWpGaD
Cisapride—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	5.93e-06	0.0012	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.91e-06	0.0012	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.91e-06	0.0012	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.81e-06	0.00118	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.81e-06	0.00118	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.78e-06	0.00117	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.78e-06	0.00117	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.69e-06	0.00115	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.69e-06	0.00115	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.61e-06	0.00114	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	5.6e-06	0.00114	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.59e-06	0.00113	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.57e-06	0.00113	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.53e-06	0.00112	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.5e-06	0.00111	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.37e-06	0.00109	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.34e-06	0.00108	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.26e-06	0.00107	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.25e-06	0.00107	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.25e-06	0.00107	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.17e-06	0.00105	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.17e-06	0.00105	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	5.15e-06	0.00105	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	5.14e-06	0.00104	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.13e-06	0.00104	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	5.11e-06	0.00104	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.06e-06	0.00103	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.99e-06	0.00101	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.91e-06	0.000996	CbGpPWpGaD
Cisapride—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.79e-06	0.000971	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.64e-06	0.00094	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.53e-06	0.000918	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.49e-06	0.000911	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.46e-06	0.000905	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.46e-06	0.000904	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.4e-06	0.000892	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.4e-06	0.000892	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.38e-06	0.000887	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.37e-06	0.000886	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.36e-06	0.000884	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.36e-06	0.000884	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.33e-06	0.000879	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.33e-06	0.000878	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.26e-06	0.000865	CbGpPWpGaD
Cisapride—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.16e-06	0.000843	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.13e-06	0.000839	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.08e-06	0.000827	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4e-06	0.00081	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.96e-06	0.000804	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.96e-06	0.000804	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.94e-06	0.000798	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.93e-06	0.000797	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.9e-06	0.000791	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.87e-06	0.000786	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.74e-06	0.000758	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.65e-06	0.00074	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.6e-06	0.00073	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.59e-06	0.000728	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.54e-06	0.000718	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.52e-06	0.000713	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.52e-06	0.000713	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.37e-06	0.000683	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.32e-06	0.000672	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.3e-06	0.000669	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.27e-06	0.000662	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.25e-06	0.000659	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.22e-06	0.000652	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.1e-06	0.000629	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.1e-06	0.000629	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.05e-06	0.000619	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.05e-06	0.000619	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.99e-06	0.000606	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.92e-06	0.000593	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.89e-06	0.000586	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.67e-06	0.000542	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.63e-06	0.000534	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.6e-06	0.000526	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.58e-06	0.000524	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.58e-06	0.000523	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.41e-06	0.000489	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.36e-06	0.000479	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.36e-06	0.000478	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.35e-06	0.000477	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.33e-06	0.000472	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.32e-06	0.000471	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.29e-06	0.000465	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.29e-06	0.000464	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.25e-06	0.000457	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.13e-06	0.000431	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.09e-06	0.000424	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.08e-06	0.000422	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	2.06e-06	0.000417	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.05e-06	0.000415	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.01e-06	0.000408	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—ALB—acquired immunodeficiency syndrome	1.89e-06	0.000382	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.73e-06	0.00035	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.72e-06	0.000348	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	1.52e-06	0.000308	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	1.49e-06	0.000302	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.39e-06	0.000282	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.39e-06	0.000281	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	1.29e-06	0.000261	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.23e-06	0.000249	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.22e-06	0.000248	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.21e-06	0.000245	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.2e-06	0.000244	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.15e-06	0.000233	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.06e-06	0.000214	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.05e-06	0.000213	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.01e-06	0.000206	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	8.96e-07	0.000182	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.18e-07	0.000166	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.22e-07	0.000146	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.11e-07	0.000144	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	6.91e-07	0.00014	CbGpPWpGaD
